David P. Nowotnik

David P. Nowotnik is a Scientific Advisor at Anokion. David was previously Senior Director of Product Development at Guilford Pharmaceuticals from January 1994 to December 1998.

At Guilford, David built and directed a team of formulation, polymer and process development scientists. David set up a cGMP facility for manufacturing a biodegradable polyanhydride, used for the manufacture of Gliadel Implant. David prepared a major part of the CMC section of the Gliadel Implant NDA and the Dopascan Injection IND. David also lead company teams in meetings with the imaging division of the FDA. David generated data and documents used for international product registration purposes. David selected and managed contract manufacturers in the manufacture of a NAALadase inhibitor and Dopascan clinical trial material.

Guilford’s products and technologies included Gliadel, a polyanhydride controlled release drug delivery product approved for treatment of glioma multiforme; Dopascan, an iodine-123-labeled tropane derivative for the diagnosis of Parkinson's disease; degradable polyphosphate and polyphosphonate polymers for paclitaxel delivery; NAALadase and PARP inhibitors for treatment of neurological disorders and cancer.

Guilford Pharmaceuticals was acquired by MGI Pharma, which was subsequently acquired by Japanese drug maker Eisai Co.

Gliadel was approved by the FDA, and is now marketed internationally. Dopascan (beta-CIT

David P. Nowotnik holds a B.Sc. in Chemistry from The University of Salford and a Ph.D. in Chemistry from the University of London.